Publication:
Real-world outcomes and progression patterns with first-line osimertinib in patients with advanced EGFR-mutant non-small cell lung cancer: a nationwide Turkish Oncology Group study

Simple item page
dc.contributor.coauthorCelayir, Ö. M.
dc.contributor.coauthorMuğlu, H.
dc.contributor.coauthorCan, O.
dc.contributor.coauthorŞen, F.
dc.contributor.coauthorÖven, B. B.
dc.contributor.coauthorDemirci, U.
dc.contributor.coauthorŞakalar, T.
dc.contributor.coauthorKarakaya, S.
dc.contributor.coauthorEr, Ö.
dc.contributor.coauthorEkinci, Ö. B.
dc.contributor.coauthorSakin, A.
dc.contributor.coauthorGür, H. B.
dc.contributor.coauthorKaraman, Y.
dc.contributor.coauthorErcan Uzundal, D.
dc.contributor.coauthorAşık, E.
dc.contributor.coauthorPilancı, K. N.
dc.contributor.coauthorAvcı, N.
dc.contributor.coauthorGürsoy, P.
dc.contributor.coauthorKaplan, M. A.
dc.contributor.coauthorMenekşe, S.
dc.contributor.coauthorKut, E.
dc.contributor.coauthorArpacı, E.
dc.contributor.coauthorKosku, H.
dc.contributor.coauthorBayram, S.
dc.contributor.coauthorŞahin, T. K.
dc.contributor.coauthorTürkmen, E.
dc.contributor.coauthorAykut, A.
dc.contributor.coauthorAğyol, Y.
dc.contributor.coauthorÖzveren, A.
dc.contributor.coauthorŞahin, E.
dc.contributor.coauthorAteş, Ö.
dc.contributor.coauthorSerin Özel, G.
dc.contributor.coauthorOyan, B.
dc.contributor.coauthorKorkmaz, T.
dc.contributor.coauthorDemir, O. G.
dc.contributor.coauthorGündüz, Ş.
dc.contributor.coauthorBilici, A.
dc.contributor.coauthorÖlmez, Ö. F.
dc.contributor.coauthorHacıbekiroğlu, İ.
dc.contributor.coauthorÇubukçu, E.
dc.contributor.coauthorYazıcı, O.
dc.contributor.coauthorYıldırım, A.
dc.contributor.coauthorBilgin, B.
dc.contributor.coauthorŞendur, M. A. N.
dc.contributor.coauthorTatlı, A. M.
dc.contributor.coauthorÖzdoğan, M.
dc.contributor.coauthorAktaş, B. Y.
dc.contributor.coauthorKanıtez, M.
dc.contributor.coauthorKarabulut, B.
dc.contributor.coauthorEkinci, F.
dc.contributor.coauthorBayram, E.
dc.contributor.coauthorGököz Doğu, G.
dc.contributor.coauthorKılıçkap, S.
dc.contributor.departmentSchool of Medicine
dc.contributor.departmentKUH (Koç University Hospital)
dc.contributor.kuauthorKöylü, Bahadır
dc.contributor.kuauthorKıkılı, Cevat İlteriş
dc.contributor.kuauthorKemik, Fatih
dc.contributor.kuauthorTural, Deniz
dc.contributor.kuauthorGündüz, Şeyda
dc.contributor.kuauthorLaçin, Şahin
dc.contributor.kuauthorDemir, Nazan
dc.contributor.kuauthorTunalı, Didem
dc.contributor.kuauthorYumuk, Perran Fulden
dc.contributor.kuauthorMandel, Nil Molinas
dc.contributor.kuauthorSelçukbiricik, Fatih
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.contributor.schoolcollegeinstituteKUH (KOÇ UNIVERSITY HOSPITAL)
dc.date.accessioned2026-07-19T19:50:17Z
dc.date.issued2026
dc.description.abstractWe aimed to evaluate the real-world outcomes of first-line osimertinib in patients with advanced EGFR-mutant non-small cell lung cancer, together with the progression patterns, including the management and outcomes of oligoprogressive disease in the real-world setting. Methods: Patients who received first-line osimertinib at 33 oncology centers across Türkiye were retrospectively analyzed. Results: The median (IQR) age of 143 patients was 59.4 (50.9–68.9), 62.9% were female, and 68.5% were non-smokers. The most frequently identified EGFR mutations were exon 19 deletion (64.3%) and exon 21 L858R (28.7%). The median progression-free survival (PFS) was 17.6 months (95% CI 14.6–20.6). Exon 19 deletion subgroup had significantly longer median PFS than exon 21 L858R subgroup (22.0 vs. 11.7 months; HR = 0.40 [95% CI 0.25–0.64]; p
dc.description.harvestedfromManual
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.publisherscopeInternational
dc.description.readpublishN/A
dc.description.sponsoredbyTubitakEuN/A
dc.description.versionPublished Version
dc.identifier.ScopusPercentile84
dc.identifier.ScopusQuartileQ1
dc.identifier.WoSPercentile72.5
dc.identifier.WoSQuartileQ2
dc.identifier.doi10.3390/cancers18121979
dc.identifier.embargoN/A
dc.identifier.issn2072-6694
dc.identifier.issue12
dc.identifier.pubmed42352512
dc.identifier.scopus2-s2.0-105043106724
dc.identifier.urihttp://doi.org/10.3390/cancers18121979
dc.identifier.urihttps://hdl.handle.net/20.500.14288/33644
dc.identifier.volume18
dc.identifier.wos001803597500001
dc.keywordsEpidermal growth factor receptor
dc.keywordsTyrosine kinase inhibitor
dc.keywordsLung neoplasms
dc.keywordsRadiotherapy
dc.languageeng
dc.publisherMDPI
dc.relation.affiliationKoç University
dc.relation.collectionKoç University Institutional Repository
dc.relation.ispartofCancers
dc.relation.openaccessN/A
dc.rightsN/A
dc.rights.uriN/A
dc.subjectHealth sciences
dc.subjectMedicine
dc.subjectOncology
dc.titleReal-world outcomes and progression patterns with first-line osimertinib in patients with advanced EGFR-mutant non-small cell lung cancer: a nationwide Turkish Oncology Group study
dc.typeJournal Article
dspace.entity.typePublication
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublicationf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication055775c9-9efe-43ec-814f-f6d771fa6dee
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files

Collections

Publications without Fulltext